Biotech Epicrispr has closed a $90 million Series C as its experimental EPI-321 therapy advances through a Phase 1/2 FSHD study. The South San Francisco company says the funding will support later-stage development, manufacturing and its epigenetic medicine platform. Here is what the financing and early clinical data show so far.
Key Takeaways
- Epicrispr Biotechnologies announced the $90 million Series C on August 11, 2026.
- EPI-321 is being studied in adults with facioscapulohumeral muscular dystrophy, or FSHD.
- Epicrispr announced on July 7 that enrollment and dose escalation in its Phase 1/2 trial were complete.
- Interim data from three evaluable participants showed increased lean muscle volume at six months, though the findings remain preliminary.
- Additional clinical data are expected later in 2026, according to the company.
Epicrispr Biotechnologies said the $90 million financing will support the development of EPI-321, additional programs built around its Gene Expression Modulation System, or GEMS, and expanded manufacturing capabilities.
The August 11 round was co-led by Octagon Capital and Janus Henderson Investors. Fidelity Management & Research Company, Cormorant Asset Management, Duquesne Family Office, Sanofi Ventures, funds managed by abrdn Inc., Angelini Ventures, Readout Capital and existing backers also participated.
“This financing positions us to advance EPI-321 into pivotal studies, expand our pipeline,” CEO Amber Salzman said in the company announcement. Any move into a pivotal study would depend on the program’s continuing clinical development.
The financing follows a $68 million Series B announced in March 2025, which supported EPI-321’s transition into human testing. For a company operating within the broader South San Francisco biotech landscape, the new round arrives as EPI-321 moves further into its first clinical study.
Early EPI-321 Data Show a Signal, Not a Verdict
EPI-321 is being evaluated in a Phase 1/2, open-label, dose-escalation trial identified as NCT06907875. ClinicalTrials.gov describes the study as assessing safety, tolerability, biological activity and possible early signs of efficacy in adults with FSHD Type 1.
Participants receive a single intravenous dose of the experimental therapy. The study is also measuring changes in DUX4 expression, methylation of the D4Z4 region, muscle imaging and other indicators of disease activity.
Epicrispr announced July 7 that enrollment and dose escalation had been completed. The ClinicalTrials.gov record, which was last updated April 22, still lists the study as recruiting, meaning the registry had not yet reflected the company’s more recent enrollment announcement when last updated.
The financing comes after Epicrispr released interim findings on June 26 from the first three evaluable participants in the initial cohort. According to the company, all three had increased lean muscle volume at six months compared with baseline. The average increase was approximately 370 milliliters, or about 0.8 pounds of muscle mass.
Those findings are preliminary and come from a very small number of participants in an uncontrolled early-stage study. An increase in muscle volume does not by itself establish improved strength, mobility or long-term clinical benefit.
Biotech Epicrispr Targets DUX4 Without Cutting DNA
Photo Credit: Unsplash.com
Biotech Epicrispr is developing EPI-321 to regulate the activity of DUX4, a gene associated with the biological processes that drive FSHD.
FSHD is a genetic muscle disorder that can affect muscles of the face, shoulders and upper arms and may progress to other muscle groups. Disease severity and progression can differ substantially among individuals.
In FSHD, reduced methylation around the D4Z4 region can permit abnormal DUX4 expression in skeletal muscle. EPI-321 is designed to re-methylate that region and suppress DUX4 activity without permanently cutting or changing the underlying DNA sequence.
The therapy uses an adeno-associated virus vector to deliver an epigenetic editor to muscle tissue. The editor includes a nuclease-dead CRISPR-associated protein designed to bind to a targeted genomic region rather than cut DNA. ClinicalTrials.gov describes measurements of DUX4 expression and D4Z4 methylation among the study’s secondary outcomes.
The approach places Epicrispr within a wider field examining how genetic and computational tools can be applied to disease research, alongside broader developments in healthcare technology in San Francisco.
South San Francisco Base Adds Local Biotech Context
Epicrispr lists its headquarters at 7000 Shoreline Court in South San Francisco, placing the company inside one of the Bay Area’s established life sciences clusters.
The financing announcement follows several clinical milestones for EPI-321. Interim data were reported June 26, enrollment and dose escalation were announced as complete July 7, and the $90 million financing followed on August 11.
The sequence shifts attention toward the additional clinical data Epicrispr says it expects later in 2026. Those results could provide more information about safety, biomarkers, muscle imaging and functional measurements across a larger group of participants.
EPI-321 remains experimental. Its safety and effectiveness have not been established, and the current study is designed in part to determine an appropriate dose and gather evidence needed to guide subsequent clinical research.
For Biotech Epicrispr, the $90 million round provides additional resources as that testing continues. The significance of the early muscle-volume findings will depend on longer follow-up, data from more participants and whether biological changes correspond with clinically meaningful outcomes.
Frequently Asked Questions
What Is Epicrispr Biotechnologies Developing?
Epicrispr Biotechnologies is developing EPI-321, an experimental epigenetic therapy for facioscapulohumeral muscular dystrophy. The therapy is designed to suppress abnormal DUX4 expression without permanently changing the underlying DNA sequence.
How Much Did Biotech Epicrispr Raise?
Biotech Epicrispr announced a $90 million Series C financing on August 11, 2026. The company says the proceeds will support EPI-321 development, other programs, manufacturing capabilities and its GEMS platform.
What Is the Status of the EPI-321 Trial?
Epicrispr announced on July 7, 2026, that enrollment and dose escalation in the Phase 1/2 first-in-human study had been completed. The company has said additional clinical data are expected later in 2026.
What Did the Early EPI-321 Results Show?
Epicrispr reported that the first three evaluable participants showed increases in lean muscle volume six months after treatment, averaging about 370 milliliters. The results remain preliminary because they involve a small number of participants in an ongoing open-label study.
Is EPI-321 an Approved Treatment for FSHD?
No. EPI-321 remains an experimental therapy being evaluated in clinical testing, and its safety and effectiveness have not been established.
